Kenvue (KVUE) Stock Surges as Q1 Earnings Crush Expectations Amid Kimberly-Clark Merger

Table of Contents Kenvue (KVUE) unveiled first-quarter financial results Thursday that significantly exceeded Wall Street projections for both earnings and sales, pushing shares up approximately 1.78% during trading. Kenvue Inc., KVUE The consumer healthcare giant announced adjusted earnings per share of $0.32, comfortably surpassing the analyst consensus range of roughly $0.26 to $0.31. Quarterly revenue totaled $3.91 billion for the period ending March 29, representing a 4.5% increase from $3.74 billion recorded in the comparable quarter last year, while also beating the anticipated $3.84 billion figure. $KVUE Q1 2026 earnings: Margins Surge While Deal Looms, But Volumes Tell a Cautious Story Kenvue's Q1 results are overshadowed by the pending Kimberly-Clark acquisition, but the standalone numbers reveal a bifurcated business. While reported revenue grew 4.5%, this was heavily… pic.twitter.com/dqI8hyQ8ik — Finsee (@Finsee_main) May 7, 2026 Organic revenue climbed 0.7%, propelled by 1.0% positive pricing impact, though partially counterbalanced by a 0.3% decrease in volume. KVUE shares had dipped 0.11% during pre-market activity before the earnings announcement, but the robust figures appeared to restore investor confidence. Chief Executive Officer Kirk Perry highlighted that the organization achieved both net and organic sales advancement for the second straight quarter, accompanied by year-over-year enhancements in gross margin, operating margin, and earnings per share. Adjusted gross profit margin expanded by 80 basis points to reach 60.8%, attributable to supply chain efficiencies and beneficial pricing strategies that mitigated inflationary pressures and tariff-related challenges. Adjusted operating income margin climbed to 24.0% compared to 19.8% in the prior-year period. The Skin Health and Beauty division emerged as the top performer, recording net sales growth of 8.4% to reach $1.06 billion. Flagship brands including Neutrogena and Aveeno fueled worldwide consumer demand. Self Care increased 1.9% while Essential Health advanced 4.9%. The Self Care category faced headwinds from an unusually mild cold and flu season throughout key markets. The organization indicated its ongoing restructuring initiative is projected to generate pre-tax expenses totaling approximately $250 million throughout the current year. Kenvue opted not to provide forward-looking guidance because of the pending $40 billion acquisition by Kimberly-Clark, anticipated to finalize during the second half of 2026, contingent upon international regulatory clearances. Kimberly-Clark shares advanced roughly 2.05% during the session, as the earnings report was perceived positively for the acquiring company. RBC Capital Markets analyst Nik Modi characterized the results as encouraging for Kimberly-Clark, stating “Kenvue’s fundamentals seem to be stabilizing.” He emphasized that near-term stock movement will probably depend more heavily on the transaction timeline and legal developments than on core business performance.